TR199901660T2 - Biyo-uygunluk derecesi y�ksek fenofibrat farmas�tik kompozisyonu ve haz�rlama y�ntemi. - Google Patents

Biyo-uygunluk derecesi y�ksek fenofibrat farmas�tik kompozisyonu ve haz�rlama y�ntemi.

Info

Publication number
TR199901660T2
TR199901660T2 TR1999/01660T TR9901660T TR199901660T2 TR 199901660 T2 TR199901660 T2 TR 199901660T2 TR 1999/01660 T TR1999/01660 T TR 1999/01660T TR 9901660 T TR9901660 T TR 9901660T TR 199901660 T2 TR199901660 T2 TR 199901660T2
Authority
TR
Turkey
Prior art keywords
preparation
pharmaceutical composition
high bioavailability
fenofibrate
hydrophilic polymer
Prior art date
Application number
TR1999/01660T
Other languages
English (en)
Turkish (tr)
Inventor
Stamm Andr
Seth Pawan
Original Assignee
Laboratoires Fournier S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9502710&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR199901660(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laboratoires Fournier S.A. filed Critical Laboratoires Fournier S.A.
Publication of TR199901660T2 publication Critical patent/TR199901660T2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TR1999/01660T 1997-01-17 1998-01-16 Biyo-uygunluk derecesi y�ksek fenofibrat farmas�tik kompozisyonu ve haz�rlama y�ntemi. TR199901660T2 (xx)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9700479A FR2758459B1 (fr) 1997-01-17 1997-01-17 Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation

Publications (1)

Publication Number Publication Date
TR199901660T2 true TR199901660T2 (xx) 1999-09-21

Family

ID=9502710

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/01660T TR199901660T2 (xx) 1997-01-17 1998-01-16 Biyo-uygunluk derecesi y�ksek fenofibrat farmas�tik kompozisyonu ve haz�rlama y�ntemi.

Country Status (35)

Country Link
US (18) US6074670A (instruction)
EP (6) EP1273293B1 (instruction)
JP (6) JP4219988B2 (instruction)
KR (2) KR100415897B1 (instruction)
CN (2) CN1496738B (instruction)
AR (1) AR011411A1 (instruction)
AT (4) ATE233556T1 (instruction)
BR (1) BR9806738A (instruction)
CA (5) CA2448630A1 (instruction)
CY (4) CY2396B1 (instruction)
CZ (1) CZ297251B6 (instruction)
DE (5) DE29825080U1 (instruction)
DK (5) DK1273294T3 (instruction)
DZ (1) DZ2398A1 (instruction)
EE (1) EE04042B1 (instruction)
EG (1) EG23978A (instruction)
ES (5) ES2241931T3 (instruction)
FR (1) FR2758459B1 (instruction)
HU (3) HU230685B1 (instruction)
ID (1) ID22528A (instruction)
IL (1) IL130790A0 (instruction)
IN (1) IN187906B (instruction)
IS (1) IS5097A (instruction)
MA (1) MA26466A1 (instruction)
NO (2) NO329200B1 (instruction)
NZ (1) NZ336462A (instruction)
PL (1) PL194802B1 (instruction)
PT (4) PT1273293E (instruction)
RU (3) RU2196580C2 (instruction)
SK (1) SK285847B6 (instruction)
TN (1) TNSN98009A1 (instruction)
TR (1) TR199901660T2 (instruction)
UA (1) UA61096C2 (instruction)
WO (1) WO1998031361A1 (instruction)
ZA (1) ZA98324B (instruction)

Families Citing this family (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7255877B2 (en) * 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
FR2758459B1 (fr) 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
FR2783421B1 (fr) * 1998-09-17 2000-11-24 Cll Pharma Procede de preparation de nouvelles formulations galeniques du fenofibrate, formulations galeniques obtenues par ledit procede et leurs applications
SE9803240D0 (sv) * 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
AU767154B2 (en) * 1998-11-20 2003-10-30 Skyepharma Canada Inc. Dispersible phospholipid stabilized microparticles
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
JP4748839B2 (ja) * 1999-03-25 2011-08-17 大塚製薬株式会社 シロスタゾール製剤
EG23951A (en) * 1999-03-25 2008-01-29 Otsuka Pharma Co Ltd Cilostazol preparation
CA2270306C (en) * 1999-04-27 2000-09-26 Bernard Charles Sherman Pharmaceutical compositions comprising co-micronized fenofibrate
US6465011B2 (en) * 1999-05-29 2002-10-15 Abbott Laboratories Formulations comprising lipid-regulating agents
US6368620B2 (en) 1999-06-11 2002-04-09 Abbott Laboratories Formulations comprising lipid-regulating agents
US6982281B1 (en) 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US7863331B2 (en) * 1999-07-09 2011-01-04 Ethypharm Pharmaceutical composition containing fenofibrate and method for the preparation thereof
FR2795961B1 (fr) * 1999-07-09 2004-05-28 Ethypharm Lab Prod Ethiques Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
FR2803203B1 (fr) * 1999-12-31 2002-05-10 Fournier Ind & Sante Nouvelles formulations galeniques du fenofibrate
US6531158B1 (en) * 2000-08-09 2003-03-11 Impax Laboratories, Inc. Drug delivery system for enhanced bioavailability of hydrophobic active ingredients
US8586094B2 (en) 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
US20080241070A1 (en) * 2000-09-21 2008-10-02 Elan Pharma International Ltd. Fenofibrate dosage forms
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
WO2002043704A1 (en) 2000-12-01 2002-06-06 Kyowa Hakko Kogyo Co., Ltd. Composition improved in solubility or oral absorbability
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
FR2819720B1 (fr) 2001-01-22 2004-03-12 Fournier Lab Sa Nouveaux comprimes de fenofibrate
ATE348649T1 (de) 2001-01-26 2007-01-15 Schering Corp Kombinationen von einem hemmer der sterol- absorption und einem ppar-aktivator zur behandlung von kardiovaskulären indikationen
PL205343B1 (pl) 2001-01-26 2010-04-30 Schering Corp Zastosowanie inhibitora wchłaniania sterolu
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
TWI288000B (en) * 2001-02-22 2007-10-11 Rtp Pharma Inc Fibrate-statin combinations with reduced fed-fasted effects
WO2002069957A1 (fr) * 2001-03-01 2002-09-12 Grelan Pharmaceutical Co., Ltd. Composition contenant du fenofibrate
CN100579514C (zh) * 2001-07-06 2010-01-13 生命周期药物公司 通过受控制的凝聚而制备颗粒物的方法以及提高生物利用度的方法
GB0119480D0 (en) * 2001-08-09 2001-10-03 Jagotec Ag Novel compositions
US20030091634A1 (en) * 2001-09-14 2003-05-15 Pawan Seth Delayed release tablet of venlafaxin
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
CA2460340C (en) 2001-09-21 2011-02-15 Schering Corporation Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
US20030118647A1 (en) * 2001-12-04 2003-06-26 Pawan Seth Extended release tablet of metformin
FR2834212B1 (fr) * 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
US20030212138A1 (en) * 2002-01-14 2003-11-13 Pharmacia Corporation Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
EP1469832B2 (en) 2002-02-01 2016-10-26 Bend Research, Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
PT1487416E (pt) * 2002-03-26 2010-01-25 Teva Pharma Micropartículas de fármacos
EP2228060A1 (en) * 2002-05-03 2010-09-15 Skyepharma Canada Inc. Oral dosage forms comprising fenofibrate
US6828334B2 (en) * 2002-05-23 2004-12-07 Usv Limited Fenofibrate-cyclodextrin inclusion complexes and their pharmaceutical composition
US20070264348A1 (en) * 2002-05-24 2007-11-15 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
FR2841138B1 (fr) * 2002-06-25 2005-02-25 Cll Pharma Composition pharmaceutique solide contenant un principe actif lipophile, son procede de preparation
US20040005339A1 (en) * 2002-06-28 2004-01-08 Shojaei Amir H. Formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability
WO2004002458A1 (en) * 2002-06-28 2004-01-08 Shire Laboratories Inc. Formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability
EP2295529B2 (en) 2002-07-11 2022-05-18 Basf As Use of a volatile environmental pollutants-decreasing working fluid for decreasing the amount of pollutants in a fat for alimentary or cosmetic use
SE0202188D0 (sv) * 2002-07-11 2002-07-11 Pronova Biocare As A process for decreasing environmental pollutants in an oil or a fat, a volatile fat or oil environmental pollutants decreasing working fluid, a health supplement, and an animal feed product
EP1553928A1 (en) * 2002-09-24 2005-07-20 Ranbaxy Laboratories, Ltd. Oral pharmaceutical compositions of fenofibrate having high bioavailability
EP2277533B1 (en) * 2002-10-23 2016-07-20 GlaxoSmithKline Biologicals S.A. Methods for vaccinating against malaria
US20040086567A1 (en) * 2002-10-30 2004-05-06 Pawan Seth Bioequivalent composition of itraconazole and a hydrophilic polymer
CA2504878A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorption inhibitors for the treatment of demyelination
CN100367947C (zh) * 2002-12-04 2008-02-13 徐州恩华赛德药业有限责任公司 具有抗高血脂症的含非诺贝特的药物组合物
CA2509101A1 (en) 2002-12-13 2004-07-01 Jagotec Ag A topical nanoparticulate spironolactone formulation
WO2004054568A1 (en) * 2002-12-17 2004-07-01 Abbott Gmbh & Co. Kg Formulation comprising fenofibric acid, a physiologically acceptable salt or derivative thereof
US20080051411A1 (en) * 2002-12-17 2008-02-28 Cink Russell D Salts of Fenofibric Acid and Pharmaceutical Formulations Thereof
US7259186B2 (en) 2002-12-17 2007-08-21 Abbott Laboratories Salts of fenofibric acid and pharmaceutical formulations thereof
US20040115287A1 (en) * 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods
US20040142903A1 (en) * 2003-01-16 2004-07-22 Par Pharmaceutical Inc. Bioavailable fenofibrate compositions, methods for treating hyperlipidemia and hypercholesterolemia and processes for the preparation of such compositions
US20040162320A1 (en) * 2003-02-14 2004-08-19 Pawan Seth Solid composition containing nisoldipine a mixture of polyethylene oxides and an antioxidant
FR2851734B1 (fr) * 2003-02-28 2006-06-09 Galenix Innovations Procede pour la fabrication d'une composition pharmaceutique sous la forme de comprimes contenant un fibrate et comprimes obtenus selon le procede
ES2318274T3 (es) 2003-03-07 2009-05-01 Schering Corporation Compuestos de azetidinona sustituida, formulaciones y uso de los mismos para el tratamiento de hipercolesterolemia.
US7192944B2 (en) * 2003-03-07 2007-03-20 Schering Corp. Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
ES2311806T3 (es) 2003-03-07 2009-02-16 Schering Corporation Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7601756B2 (en) * 2003-06-06 2009-10-13 Snowden Pharmaceuticals, Llc Method of treatment for irritable bowel syndrome
DE10325989A1 (de) * 2003-06-07 2005-01-05 Glatt Gmbh Verfahren zur Herstellung von und daraus resultierende Mikropellets sowie deren Verwendung
FR2857591B1 (fr) * 2003-07-17 2007-11-02 Ethypharm Sa Particules comprenant un principe actif sous forme de co-precipite
BRPI0413277A (pt) 2003-08-04 2006-10-10 Pfizer Prod Inc composições farmacêuticas de adsorvatos de medicamentos amorfos e materiais que formam microfases lipofìlicas
US20050096390A1 (en) * 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and pravastatin
US7658944B2 (en) * 2003-10-10 2010-02-09 Lifecycle Pharma A/S Solid dosage form comprising a fibrate
EP1680086A2 (en) * 2003-10-10 2006-07-19 LifeCycle Pharma A/S A solid dosage form comprising a fibrate and a statin
US20050096391A1 (en) * 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and rosuvastatin
US20070014846A1 (en) * 2003-10-10 2007-01-18 Lifecycle Pharma A/S Pharmaceutical compositions comprising fenofibrate and atorvastatin
US9173847B2 (en) * 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
US20050142203A1 (en) * 2003-12-30 2005-06-30 Grant Heinicke Oral dosage formulations of active pharmaceutical ingredients and methods of preparing the same
DE102004002761B4 (de) * 2004-01-20 2017-01-05 Daimler Ag Verfahren zum Betrieb eines Antriebsstrangs eines Kraftfahrzeugs
EP1559419A1 (en) * 2004-01-23 2005-08-03 Fournier Laboratories Ireland Limited Pharmaceutical formulations comprising metformin and a fibrate, and processes for their obtention
EP1568369A1 (en) 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the treatment of respiratory diseases in pigs
FR2868079B1 (fr) * 2004-03-29 2007-06-08 Seppic Sa Tensioactifs sous forme de poudre utilisables dans des comprimes ou des gelules procede de preparation et compositions les contenant
US7244765B2 (en) 2004-06-25 2007-07-17 Cytokine Pharmasciences, Inc Guanylhydrazone salts, compositions, processes of making and methods of using
US20060024362A1 (en) 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
US8026281B2 (en) * 2004-10-14 2011-09-27 Lupin Atlantis Holdings, S.A. Treating metabolic syndrome with fenofibrate
WO2006060817A1 (en) * 2004-12-03 2006-06-08 Abbott Laboratories Pharmaceutical compositions
CA2589656A1 (en) * 2004-12-06 2006-06-15 Reliant Pharmaceuticals, Inc. Stable compositions of fenofibrate with fatty acid esters
BRPI0518398A2 (pt) * 2004-12-06 2008-11-18 Reliant Pharmaceuticals Inc Ácidos graxos âmega-3 e agente deslipidÊmico para terapia de lipÍdeos
CN101098690A (zh) * 2004-12-06 2008-01-02 瑞莱恩特医药品有限公司 用于血脂治疗的ω-3脂肪酸和脂血异常剂
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
EP1841450A4 (en) * 2005-01-14 2013-04-17 Avax Technologies Inc METHOD FOR PRODUCING A VACCINE FOR THE TREATMENT OF CANCER
NZ560232A (en) * 2005-02-25 2010-11-26 Hoffmann La Roche Tablets with improved drug substance dispersibility
JP2006273849A (ja) * 2005-03-02 2006-10-12 Aska Pharmaceutical Co Ltd フェノフィブラート含有組成物
CA2600429A1 (en) * 2005-03-08 2006-09-14 Reliant Pharmaceuticals, Inc. Treatment with statin and omega-3 fatty acids and a combination product thereof
KR20070113289A (ko) * 2005-03-30 2007-11-28 테바 파마슈티컬 인더스트리즈 리미티드 멘톨 또는 ｐｅｇ/폴록사머를 함유하는 개선된페노피브레이트 제제
EP1707197A1 (en) 2005-03-30 2006-10-04 Teva Pharmaceutical Industries Ltd. Formulations containing fenofibrate and a surfactant mixture
US20060222707A1 (en) * 2005-03-30 2006-10-05 Lerner E I Formulations of fenofibrate
US20070148233A1 (en) * 2005-12-28 2007-06-28 Lerner E I Pharmaceutical formulations of fenofibrate having improved bioavailability
EP2074992B1 (en) * 2005-04-08 2015-05-20 Abbott Laboratories Oral pharmaceutical formulations comprising salts of fenofibric acid
US20080152714A1 (en) * 2005-04-08 2008-06-26 Yi Gao Pharmaceutical Formulations
US20070185199A1 (en) * 2005-04-08 2007-08-09 Ju Tzuchi R Pharmaceutical formulations
US20070148234A1 (en) * 2005-04-08 2007-06-28 Ju Tzuchi R Pharmaceutical formulations
CN101222911A (zh) * 2005-07-15 2008-07-16 特瓦制药工业有限公司 新的制粒方法及由此制备的颗粒
US20070014854A1 (en) * 2005-07-15 2007-01-18 Ilan Zalit Novel granulation process
US20070014853A1 (en) * 2005-07-15 2007-01-18 Ilan Zalit Pharmaceutical dosage form containing novel pharmaceutical granulate
US20070015834A1 (en) * 2005-07-18 2007-01-18 Moshe Flashner-Barak Formulations of fenofibrate containing PEG/Poloxamer
US20070015833A1 (en) * 2005-07-18 2007-01-18 Moshe Flashner-Barak Formulations of fenofibrate containing menthol
DE102005047561A1 (de) * 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
EP1785133A1 (en) * 2005-11-10 2007-05-16 Laboratoires Fournier S.A. Use of fenofibrate or a derivative thereof for preventing diabetic retinopathy
DK1803441T3 (da) 2005-12-28 2009-08-03 Teva Pharma Farmaceutiske fenofibrat-formuleringer, der har forbedret biotilgængelighed
WO2007075171A1 (en) * 2005-12-28 2007-07-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical formulations of fenofibrate having improved bioavailability
US20090252790A1 (en) * 2006-05-13 2009-10-08 Novo Nordisk A/S Tablet formulation
EP2452683A3 (en) 2006-06-26 2012-08-22 Amgen Inc. Methods for treating atherosclerosis
EP2037888A2 (en) * 2006-06-26 2009-03-25 Mutual Pharmaceutical Company, Inc. Active agent formulations, methods of making, and methods of use
US20090074872A1 (en) * 2006-06-26 2009-03-19 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
WO2008033024A2 (en) 2006-09-15 2008-03-20 Echo Pharmaceuticals B.V. Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances
PL2061427T3 (pl) * 2006-09-15 2011-12-30 Echo Pharmaceuticals Bv Granulat zawierający substancję farmaceutycznie aktywną i emulgator oraz sposób jego wytwarzania
US20080090903A1 (en) * 2006-10-13 2008-04-17 Pandey Ramendra N Phenylalkyl carbamate compositions
WO2008104852A2 (en) * 2007-02-26 2008-09-04 Wockhardt Research Centre Pharmaceutical compositions comprising adsorbate of fenofibrate
WO2008109018A1 (en) * 2007-03-02 2008-09-12 Meda Pharmaceuticals Inc. Compositions comprising carisoprodol and methods of use thereof
US7872560B2 (en) * 2007-03-19 2011-01-18 Abc Taiwan Electronics Corp. Independent planar transformer
MY159075A (en) 2007-07-26 2016-12-15 Amgen Inc Modified lecithin-cholesterol acyltransferase enzymes
US20100285126A1 (en) * 2007-08-02 2010-11-11 Rahul Dabre Pharmaceutical compositions of fenofibrate
US9254268B2 (en) * 2007-09-25 2016-02-09 Solubest Ltd. Compositions comprising lipophilic active compounds and method for their preparation
US20090202649A1 (en) * 2008-02-06 2009-08-13 Subhash Gore Fenofibrate formulations
AU2009224418B2 (en) 2008-03-11 2014-12-11 Aska Pharmaceutical Co., Ltd. Solid dispersion, pharmaceutical compositions containing the same, and processes for the production of both
US8524280B2 (en) * 2008-12-15 2013-09-03 Banner Pharmacaps, Inc. Methods for enhancing the release and absorption of water insoluble active agents
US20100159010A1 (en) * 2008-12-24 2010-06-24 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
FR2940118B1 (fr) 2008-12-24 2013-08-09 Ethypharm Sa Formulation pharmaceutique de fenofibrate nanonise
UA106596C2 (uk) 2009-01-02 2014-09-25 Ебботт Леборетріз, Аєленд, Лімітед Нове застосування фібратів
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
JPWO2010092925A1 (ja) * 2009-02-12 2012-08-16 あすか製薬株式会社 固体分散体とその医薬組成物、並びにそれらの製造方法
JP2012527491A (ja) 2009-05-27 2012-11-08 サムヤン バイオファーマシューティカルズ コーポレイション 生体利用率が向上した難溶性薬物含有微粒球およびその製造方法
US20110217369A1 (en) * 2009-09-03 2011-09-08 Ranbaxy Laboratories Limited Fenofibrate compositions
KR100980752B1 (ko) * 2009-12-17 2010-09-07 삼일제약주식회사 담체 표면 상에 흡착된 페노피브레이트를 포함하는 과립 및 이를 포함하는 약학 조성물
KR101202994B1 (ko) 2010-04-12 2012-11-21 한미사이언스 주식회사 페노피브린산 및 알칼리화제를 포함하는 경구용 약학 조성물
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets
WO2011143172A1 (en) 2010-05-11 2011-11-17 Thorium Power, Inc. Fuel assembly with metal fuel alloy kernel and method of manufacturing thereof
US10192644B2 (en) 2010-05-11 2019-01-29 Lightbridge Corporation Fuel assembly
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
GB201118182D0 (en) 2011-10-21 2011-12-07 Jagotec Ag Improvements in or relating to organic compounds
WO2013064853A1 (en) 2011-11-05 2013-05-10 Lupin Atlantis Holdings, S.A. Reduced dose oral pharmaceutical compositions of fenofibrate
MX368200B (es) 2011-12-08 2019-09-24 Amgen Inc Proteinas de union al antigeno lecitin colesterol aciltransferasas humanas agonistas y su uso en terapia.
US9452107B2 (en) 2012-04-16 2016-09-27 New Jersey Institute Of Technology Systems and methods for superdisintegrant-based composite particles for dispersion and dissolution of agents
US9439860B2 (en) 2012-06-25 2016-09-13 Mylan, Inc. Fenofibrate formulation
US8722083B2 (en) * 2012-06-25 2014-05-13 Mylan, Inc. Fenofibrate formulation
WO2014091318A1 (en) 2012-12-11 2014-06-19 Lupin Atlantis Holdings, S.A. Reduced dose pharmaceutical compositions of fenofibrate
EP2842547A1 (en) 2013-08-27 2015-03-04 Freund Pharmatec Ltd. Improved fenofibrate compositions
CN105636582A (zh) 2013-09-18 2016-06-01 乔治城大学 用非诺贝特及其类似物治疗神经退行性疾病
KR101576587B1 (ko) * 2014-02-05 2015-12-10 한양대학교 에리카산학협력단 신규한 페노피브레이트 함유 젤라틴 나노입자
WO2015191282A1 (en) 2014-06-11 2015-12-17 Mallinckrodt Llc Spray dried compositions having different dissolution profiles and processes for their preparation
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
CN104352466A (zh) * 2014-11-17 2015-02-18 辰欣药业股份有限公司 一种非诺贝特组合物及其制剂
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
CN104922078B (zh) * 2015-06-23 2018-10-23 上海市计划生育科学研究所 非诺贝特迟释微丸、制备方法及应用
KR20180118719A (ko) 2016-03-04 2018-10-31 다이호야쿠힌고교 가부시키가이샤 악성 종양 치료용 제제 및 조성물
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
CA3078723A1 (en) 2016-11-28 2018-05-31 Nachiappan Chidambaram Oral testosterone undecanoate therapy
CN107049981A (zh) * 2017-04-11 2017-08-18 深圳市泛谷药业股份有限公司 一种速释氨磺必利药物组合物及其制备方法
US11534493B2 (en) 2017-09-22 2022-12-27 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
HUE067430T2 (hu) 2018-03-19 2024-10-28 Taiho Pharmaceutical Co Ltd Nátrium-laurilszulfátot tartalmazó gyógyászati készítmény
CA3107214A1 (en) 2018-07-20 2020-01-23 Lipocine Inc. Liver disease
AU2020320448B2 (en) * 2019-07-31 2025-05-15 Intas Pharmaceuticals Ltd. Pharmaceutical composition comprising HMG-CoA reductase inhibitors and fenofibrate
EP3943071B1 (de) 2020-03-31 2025-06-18 Zurab Durmischchanowitch Khinikadze Zusammensetzung, enthaltend natürliche lipophile verbindungen, verwendung der zusammensetzung und verfahren zur herstellung der zusammensetzung
KR102489384B1 (ko) * 2020-09-29 2023-01-18 애드파마 주식회사 생체이용율이 개선된 페노피브레이트 입자를 포함하는 약제학적 조성물
CN120166935A (zh) 2022-09-15 2025-06-17 阿尔库缇斯生物疗法股份有限公司 罗氟司特和能够溶解大量该药物的溶剂的药物组合物
CN119700739B (zh) * 2025-02-26 2025-06-20 中国人民解放军总医院第三医学中心 非诺贝特在治疗Fuchs角膜内皮营养不良中的应用

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US92597A (en) * 1869-07-13 Improved counterpoise gun-carriage
US104051A (en) * 1870-06-07 Improvement in handles of sheet-metal spoons, forks
US114839A (en) * 1871-05-16 Improvement in apparatus for aerating beer-barrels
US57997A (en) * 1866-09-11 Improvement in malt-ksln floors
US57999A (en) * 1866-09-11 Improved composition for roofing
US6655A (en) * 1849-08-21 Eirepboof safe
US57998A (en) * 1866-09-11 Improvement in broom-heads
US5783A (en) * 1848-09-19 Spinoabdominal supporter
US168413A (en) * 1875-10-05 Improvement in hydrants
US9496A (en) * 1852-12-21 Method of measuring cloth on the cloth-beam
US58005A (en) * 1866-09-11 Improvement in distilling petroleum and other liquids
US58004A (en) * 1866-09-11 Improved lap-joint for belting
US104060A (en) * 1870-06-07 Improvement in organ-bellows
US2953497A (en) * 1953-06-03 1960-09-20 Howard A Press Therapeutic tablets
US2776996A (en) * 1955-12-22 1957-01-08 Du Pont Manufacture of beta-methylmercaptopropionaldehyde
CH543472A (fr) 1969-01-31 1973-10-31 Orchimed Sa Procédé pour la préparation d'acides phénoxyalcoyl-carboxyliques
FR2314917A1 (fr) * 1975-06-20 1977-01-14 Rhone Poulenc Ind Procede de fabrication de l'aldehyde beta-methylthiopropionique
GB1579818A (en) * 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
DE2966564D1 (en) 1978-11-20 1984-02-23 American Home Prod Therapeutic compositions with enhanced bioavailability and process for their preparation
US4344934A (en) * 1978-11-20 1982-08-17 American Home Products Corporation Therapeutic compositions with enhanced bioavailability
FR2494112B1 (instruction) * 1980-11-19 1986-01-10 Laruelle Claude
DE3107933A1 (de) * 1981-03-02 1982-09-16 Cassella Ag, 6000 Frankfurt Substituierte 3-amino-sydnonimine, verfahren zu ihrer herstellung und ihre verwendung
ZA822995B (en) * 1981-05-21 1983-12-28 Wyeth John & Brother Ltd Slow release pharmaceutical composition
US4463743A (en) * 1981-12-14 1984-08-07 Brunswick Corporation Capacitor discharge ignition system for internal combustion engines
FR2532706B1 (fr) * 1982-09-07 1987-04-30 Renault Dispositif d'amortissement et vibrations d'un coupleur elastique en milieu humide, en particulier pour convertisseur de couple
DE3247118A1 (de) * 1982-12-20 1984-06-20 Cassella Ag, 6000 Frankfurt Neue substituierte 1,4-dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
IE55745B1 (en) * 1983-04-06 1991-01-02 Elan Corp Plc Sustained absorption pharmaceutical composition
US4684516A (en) * 1983-08-01 1987-08-04 Alra Laboratories, Inc. Sustained release tablets and method of making same
FR2557459B1 (fr) 1984-01-02 1986-05-30 Lhd Lab Hygiene Dietetique Matrice inerte a base de polycaprolactone pour administration orale d'un medicament, et procede de preparation de la forme galenique comprenant cette matrice
GB8414220D0 (en) * 1984-06-04 1984-07-11 Sterwin Ag Medicaments in unit dose form
GB8414221D0 (en) * 1984-06-04 1984-07-11 Sterwin Ag Unit dosage form
IT1180507B (it) 1984-06-29 1987-09-23 Roberto Valducci Procedimento per la preparazione di etofibrato o sostanze di pari o simili caratteristiche, in microgunuli-ritardo e prodotto ottenuto con tale procedimento
US4721709A (en) 1984-07-26 1988-01-26 Pyare Seth Novel pharmaceutical compositions containing hydrophobic practically water-insoluble drugs adsorbed on pharmaceutical excipients as carrier; process for their preparation and the use of said compositions
EP0179583A1 (en) 1984-10-04 1986-04-30 Merck & Co. Inc. A system for enhancing the water dissolution rate and solubility of poorly soluble drugs
US4649082A (en) 1985-03-07 1987-03-10 Ppg Industries, Inc. Radiation curable compositions based on radiation curable esters of polyfunctional hydroxyl-containing carboxylic acids
US4716033A (en) 1986-03-27 1987-12-29 Warner-Lambert Company Medicament adsorbates with surfactant and their preparation
FR2602423B1 (fr) * 1986-08-08 1989-05-05 Ethypharm Sa Procede de preparation d'un medicament a base de fenofibrate, medicament obtenu par ce procede
US5385938B1 (en) * 1986-12-23 1997-07-15 Tristrata Inc Method of using glycolic acid for treating wrinkles
CH668553A5 (de) * 1987-02-02 1989-01-13 Mepha Ag Arzneimittel mit verzoegerter wirkstofffreisetzung.
US4859703A (en) * 1987-06-15 1989-08-22 Warner-Lambert Company Lipid regulating compositions
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
DE3807895A1 (de) * 1988-03-10 1989-09-21 Knoll Ag Erzeugnisse, enthaltend einen calciumantagonisten und einen lipidsenker
DE3830353A1 (de) * 1988-09-07 1990-03-15 Basf Ag Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen
US4961891A (en) * 1988-10-04 1990-10-09 Garlock, Inc. Method of making high compressibility gasket material
US4927639A (en) * 1989-02-02 1990-05-22 Warner-Lambert Company Modified release gemfibrozil composition
US4992277A (en) * 1989-08-25 1991-02-12 Schering Corporation Immediate release diltiazem formulation
GB9015872D0 (en) * 1990-07-19 1990-09-05 Secr Defence Production of ceramic filaments
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
ATE156707T1 (de) * 1991-06-21 1997-08-15 Ilsan Ilac Ve Hammaddeleri San Neues galenisches verfahren für omeprazol enthaltende pellets
FR2692146B1 (fr) * 1992-06-16 1995-06-02 Ethypharm Sa Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention.
PH30929A (en) 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
IT1264020B (it) * 1993-01-28 1996-09-09 Recordati Chem Pharm Procedimento per la preparazione di microgranuli idonei alla sospensione in liquidi
US5905171A (en) * 1995-06-22 1999-05-18 Novus International, Inc. Process for the preparation of 3-(methylthio)propanal
US5549906A (en) * 1993-07-26 1996-08-27 Pharmacia Ab Nicotine lozenge and therapeutic method for smoking cessation
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
SE9402422D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New beads for controlled release and a pharmaceutical preparation containing the same
FR2722984B1 (fr) * 1994-07-26 1996-10-18 Effik Lab Procede de preparation de formes pharmaceutiques seches et les compositions pharmaceutiques ainsi realisees
FR2723586A1 (fr) 1994-08-11 1996-02-16 Seth Pawan Nouvelles compositions contenant de la cimetidine et associations en derivant
FR2723536A1 (fr) * 1994-08-11 1996-02-16 Seth Pawan Composition permettant une liberation selective d'un principe actif
US5545628A (en) 1995-01-10 1996-08-13 Galephar P.R. Inc. Pharmaceutical composition containing fenofibrate
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US6117453A (en) * 1995-04-14 2000-09-12 Pharma Pass Solid compositions containing polyethylene oxide and an active ingredient
US6348469B1 (en) * 1995-04-14 2002-02-19 Pharma Pass Llc Solid compositions containing glipizide and polyethylene oxide
SI9500173B (sl) * 1995-05-19 2002-02-28 Lek, Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
ES2236628T3 (es) * 1995-09-21 2005-07-16 Pharma Pass Ii Llc Composicion farmaceutica que contiene un omeprazol labil de acido, y procedimiento para su preparacion.
DE19608750A1 (de) * 1996-03-06 1997-09-11 Durachemie Gmbh & Co Kg Verfahren zur Herstellung von Fenofibrat-Präparaten
US6048547A (en) * 1996-04-15 2000-04-11 Seth; Pawan Process for manufacturing solid compositions containing polyethylene oxide and an active ingredient
FR2758459B1 (fr) 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
FR2758461A1 (fr) 1997-01-17 1998-07-24 Pharma Pass Composition pharmaceutique presentant une biodisponibilite elevee et son procede de preparation
US5952396A (en) * 1997-06-16 1999-09-14 Raychem Corporation Low modulus elastomer
CA2214895C (en) * 1997-09-19 1999-04-20 Bernard Charles Sherman Improved pharmaceutical composition comprising fenofibrate
US6027747A (en) 1997-11-11 2000-02-22 Terracol; Didier Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
US6334192B1 (en) * 1998-03-09 2001-12-25 Ronald S. Karpf Computer system and method for a self administered risk assessment
US6096341A (en) * 1998-10-30 2000-08-01 Pharma Pass Llc Delayed release tablet of bupropion hydrochloride
US6033686A (en) * 1998-10-30 2000-03-07 Pharma Pass Llc Controlled release tablet of bupropion hydrochloride
US6375986B1 (en) * 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US6180138B1 (en) 1999-01-29 2001-01-30 Abbott Laboratories Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption
US6368622B2 (en) 1999-01-29 2002-04-09 Abbott Laboratories Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption
GB2363866B (en) * 2000-05-31 2002-11-06 Intamission Ltd Data processing apparatus, method and system
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
DE60115279T2 (de) * 2000-09-29 2006-12-28 Topotarget Uk Ltd., Abingdon Carbaminsäurederivate enthaltend eine amidgruppe als hdac-inhibitoren
WO2003013500A1 (en) 2001-08-07 2003-02-20 Laboratoires Smb Sa Improved pharmaceutical composition containing a ppar alpha agent and a process for preparing it
EP1414496B1 (en) * 2001-08-07 2010-10-20 Galephar M/F Pharmaceutical composition containing a combinaition of ppar-alpha, pravastatin and polyglycolized glyceride

Also Published As

Publication number Publication date
HUP0000808A2 (hu) 2000-12-28
EP1273294B1 (fr) 2005-10-26
WO1998031361A1 (fr) 1998-07-23
CA2219475C (fr) 2002-07-09
US20080063726A1 (en) 2008-03-13
EP1468681A1 (fr) 2004-10-20
DK1275387T3 (da) 2006-08-28
CZ297251B6 (cs) 2006-10-11
PT1275387E (pt) 2006-08-31
DZ2398A1 (fr) 2003-06-04
PT952829E (pt) 2003-07-31
US20020168413A1 (en) 2002-11-14
EP0952829A1 (fr) 1999-11-03
IN187906B (instruction) 2002-07-20
CA2448630A1 (fr) 1998-07-17
CA2372576C (fr) 2004-02-10
DE69832108D1 (de) 2005-12-01
US20040057999A1 (en) 2004-03-25
JP2005206614A (ja) 2005-08-04
ZA98324B (en) 1998-08-12
US20030104051A1 (en) 2003-06-05
EP1273293B1 (fr) 2005-03-30
DE69829591D1 (de) 2005-05-04
PT2050445E (pt) 2013-08-23
US7037529B2 (en) 2006-05-02
CY2513B1 (en) 2005-12-23
SK285847B6 (sk) 2007-09-06
US20080064759A1 (en) 2008-03-13
ES2254569T3 (es) 2006-06-16
NO329200B1 (no) 2010-09-13
DE29825080U1 (de) 2004-11-04
RU2002109746A (ru) 2004-03-20
ES2263714T3 (es) 2006-12-16
NZ336462A (en) 2000-09-29
CA2219475A1 (fr) 1998-07-17
HUP0000808A3 (en) 2001-02-28
ES2427252T5 (es) 2022-02-14
US6652881B2 (en) 2003-11-25
SK96299A3 (en) 2000-08-14
DK0952829T3 (da) 2003-06-23
UA61096C2 (uk) 2003-11-17
CY2547B1 (fr) 2008-07-02
US6596317B2 (en) 2003-07-22
JP4219988B2 (ja) 2009-02-04
ATE324885T1 (de) 2006-06-15
US8343540B2 (en) 2013-01-01
EP1273293A1 (fr) 2003-01-08
US8329214B2 (en) 2012-12-11
HU228849B1 (hu) 2013-06-28
RU2196580C2 (ru) 2003-01-20
MA26466A1 (fr) 2004-12-20
NO993519D0 (no) 1999-07-16
HU227758B1 (hu) 2012-02-28
KR100391104B1 (ko) 2003-07-12
PL334748A1 (en) 2000-03-13
DK2050445T3 (da) 2013-09-08
US20040057997A1 (en) 2004-03-25
NO20100034L (no) 1999-09-16
US6277405B1 (en) 2001-08-21
ES2427252T3 (es) 2013-10-30
DE69834437T2 (de) 2006-11-16
EP1273294A1 (fr) 2003-01-08
CA2372561A1 (fr) 1998-07-17
FR2758459B1 (fr) 1999-05-07
CY2396B1 (en) 2004-09-10
US6074670A (en) 2000-06-13
EP2050445A3 (fr) 2009-09-09
JP2001511156A (ja) 2001-08-07
JP2009143967A (ja) 2009-07-02
CN1496738B (zh) 2011-03-30
EE9900296A (et) 2000-02-15
HU230685B1 (en) 2017-08-28
DK2050445T4 (da) 2021-10-18
JP4365343B2 (ja) 2009-11-18
ES2241931T3 (es) 2005-11-01
EG23978A (fr) 2008-02-26
JP2009120623A (ja) 2009-06-04
PL194802B1 (pl) 2007-07-31
IL130790A0 (en) 2001-01-28
DE69834437D1 (de) 2006-06-08
AU5336798A (en) 1998-08-07
RU2236850C2 (ru) 2004-09-27
BR9806738A (pt) 2000-02-29
US20040057998A1 (en) 2004-03-25
EP2050445B1 (fr) 2013-06-26
AU731964B2 (en) 2001-04-05
CN1243438A (zh) 2000-02-02
ID22528A (id) 1999-10-28
US20020009496A1 (en) 2002-01-24
ES2195308T3 (es) 2003-12-01
HK1023071A1 (en) 2000-09-01
EE04042B1 (et) 2003-06-16
HK1131051A1 (en) 2010-01-15
TNSN98009A1 (fr) 2005-03-15
ATE233556T1 (de) 2003-03-15
US6589552B2 (en) 2003-07-08
EP0952829B1 (fr) 2003-03-05
US20070184103A1 (en) 2007-08-09
US20040092597A1 (en) 2004-05-13
DK1273293T3 (da) 2005-06-27
JP2007326878A (ja) 2007-12-20
CZ253599A3 (cs) 1999-11-17
EP1275387A1 (fr) 2003-01-15
DE69829591T2 (de) 2006-02-09
EP2050445A2 (fr) 2009-04-22
PT1273293E (pt) 2005-06-30
IS5097A (is) 1999-06-29
AR011411A1 (es) 2000-08-16
JP4943975B2 (ja) 2012-05-30
US20090035379A1 (en) 2009-02-05
RU2238089C2 (ru) 2004-10-20
CA2372576A1 (fr) 1998-07-17
US20070190136A1 (en) 2007-08-16
EP1275387B1 (fr) 2006-05-03
NO993519L (no) 1999-09-16
CA2448623A1 (fr) 1998-07-17
EP2050445B2 (fr) 2021-07-21
DE69811855D1 (de) 2003-04-10
US20040058004A1 (en) 2004-03-25
US20040058005A1 (en) 2004-03-25
HK1065952A1 (en) 2005-03-11
DE69811855T2 (de) 2003-12-18
CN1496738A (zh) 2004-05-19
CY2560B1 (fr) 2008-07-02
FR2758459A1 (fr) 1998-07-24
US7041319B2 (en) 2006-05-09
US20030104060A1 (en) 2003-06-05
JP2011173927A (ja) 2011-09-08
HU0400409D0 (hu) 2004-04-28
US20020114839A1 (en) 2002-08-22
DE69832108T2 (de) 2006-09-21
DK1273294T3 (da) 2006-03-13
CN1278678C (zh) 2006-10-11
KR100415897B1 (ko) 2004-01-24
KR20000070021A (ko) 2000-11-25
ATE291911T1 (de) 2005-04-15
ATE307576T1 (de) 2005-11-15

Similar Documents

Publication Publication Date Title
TR199901660T2 (xx) Biyo-uygunluk derecesi y�ksek fenofibrat farmas�tik kompozisyonu ve haz�rlama y�ntemi.
RU93004469A (ru) Формы дозирования, обеспечивающие продленное выделение активного ингредиента
GB9923841D0 (en) Composition and method for enhancing transport across biological membranes
FI97690B (fi) Lääkkeen vapautumista kontrolloiva koostumus
DE69623087D1 (de) Brausemittel und dessen Herstellung
TR199902199T2 (xx) Siklosporin tatbiki i�in hidrofilik ikili sistemler.
NO20016108L (no) Kontrollert frigivelse og smaks maskerende orale farmasöytiske sammensetninger
CA2037101A1 (en) Omeprazole Compositions Designed for Administration in Rectum
RU95105449A (ru) Пероральный препарат морфина с регулируемым выделением активного компонента
CA2146757A1 (en) Stabilization of fluorocarbon emulsions
ATA189395A (de) Orale pharmazeutische zubereitung
EP1652516A3 (en) Osmotic controlled delivery of active agents
DK0519870T3 (da) hidtil ukendt diclofenacpræparat til oral administration
DK278288A (da) Frigivelsessystem til laegemiddel ved anvendelse i mundhulen og en fremgangsmaade til fremstilling af dette frigivelsesystem
CY1105262T1 (el) Φαρμακευτικες συνθεσεις παρατεταμενης απελευθερωσης για την παρεντepικη χορηγηση βιολογικως δραστικων υδροφιλων ενωσεων
CA2274565A1 (en) Hydroalcoholic compositions for transdermal penetration of pharmaceutical agents
RU93046255A (ru) Многослойная термоусадочная пленка и мешок, изготовленный из нее
SE9704400D0 (sv) Porous inorganic particles as carriers for drug substances
ES8702137A1 (es) Procedimiento de preparar una forma solidad de administracion farmaceutica para uso oral.
FI971833A0 (fi) Lapsiturvallinen pakkaus vaikuttavaa ainetta sisältävää laastaria varten
FR2748209B1 (fr) Composition pharmaceutique a base de matrices lipophiles stabilisees pour la liberation controlee de principes actifs
CA2185883A1 (en) The use of dimeticone as a transport and carrier system and/or drug delivery system
GEP20033012B (en) Liquid Polymeric Compositions for Controlled Release of Bioactive Substances
DE59108093D1 (de) Spermicides Beschichtungsmittel
KR930005615A (ko) 페이스트 및 페이스트 제제